Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154648093> ?p ?o ?g. }
- W3154648093 endingPage "1070" @default.
- W3154648093 startingPage "1062" @default.
- W3154648093 abstract "An effective vaccine is needed to end the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we assess the preliminary safety, tolerability and immunogenicity data from an ongoing single-center (in Jiangsu province, China), parallel-group, double-blind phase 1 trial of the vaccine candidate BNT162b1 in 144 healthy SARS-CoV-2-naive Chinese participants. These participants are randomized 1:1:1 to receive prime and boost vaccinations of 10 µg or 30 µg BNT162b1 or placebo, given 21 d apart, with equal allocation of younger (aged 18–55 years) and older adults (aged 65–85 years) to each treatment group (ChiCTR2000034825). BNT162b1 encodes the SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD) and is one of several messenger RNA-based vaccine candidates under clinical investigation. Local reactions and systemic events were generally dose dependent, transient and mild to moderate. Fever was the only grade 3 adverse event. BNT162b1 induced robust interferon-γ T cell responses to a peptide pool including the RBD in both younger and older Chinese adults, and geometric mean neutralizing titers reached 2.1-fold (for younger participants) and 1.3-fold (for the older participants) that of a panel of COVID-19 convalescent human sera obtained at least 14 d after positive SARS-CoV-2 polymerase chain reaction test. In summary, BNT162b1 has an acceptable safety profile and produces high levels of humoral and T cell responses in an Asian population. Phase 1 trial results of the messenger RNA vaccine candidate BNT162b1, which encodes the receptor-binding domain of the SARS-CoV-2 spike protein, show safety and elicitation of antibody and T cell responses in both younger and older Chinese adults." @default.
- W3154648093 created "2021-04-26" @default.
- W3154648093 creator A5000036560 @default.
- W3154648093 creator A5002455597 @default.
- W3154648093 creator A5003993218 @default.
- W3154648093 creator A5006067953 @default.
- W3154648093 creator A5012258151 @default.
- W3154648093 creator A5020987329 @default.
- W3154648093 creator A5026189241 @default.
- W3154648093 creator A5028130589 @default.
- W3154648093 creator A5028939852 @default.
- W3154648093 creator A5029140232 @default.
- W3154648093 creator A5031804038 @default.
- W3154648093 creator A5043379267 @default.
- W3154648093 creator A5048201566 @default.
- W3154648093 creator A5049507373 @default.
- W3154648093 creator A5060962650 @default.
- W3154648093 creator A5073018144 @default.
- W3154648093 creator A5075617216 @default.
- W3154648093 creator A5077529566 @default.
- W3154648093 creator A5077645027 @default.
- W3154648093 creator A5081596967 @default.
- W3154648093 creator A5085720070 @default.
- W3154648093 creator A5090047708 @default.
- W3154648093 date "2021-04-22" @default.
- W3154648093 modified "2023-10-15" @default.
- W3154648093 title "Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study" @default.
- W3154648093 cites W1963706689 @default.
- W3154648093 cites W2039422212 @default.
- W3154648093 cites W2047882003 @default.
- W3154648093 cites W2058647478 @default.
- W3154648093 cites W2087802416 @default.
- W3154648093 cites W2802953285 @default.
- W3154648093 cites W2885263529 @default.
- W3154648093 cites W2903777694 @default.
- W3154648093 cites W2915991550 @default.
- W3154648093 cites W3001118548 @default.
- W3154648093 cites W3007643904 @default.
- W3154648093 cites W3015281372 @default.
- W3154648093 cites W3034425032 @default.
- W3154648093 cites W3043722389 @default.
- W3154648093 cites W3047091198 @default.
- W3154648093 cites W3048620154 @default.
- W3154648093 cites W3088489318 @default.
- W3154648093 cites W3090717270 @default.
- W3154648093 cites W3090844627 @default.
- W3154648093 cites W3093367571 @default.
- W3154648093 cites W3113031614 @default.
- W3154648093 cites W3126657865 @default.
- W3154648093 doi "https://doi.org/10.1038/s41591-021-01330-9" @default.
- W3154648093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33888900" @default.
- W3154648093 hasPublicationYear "2021" @default.
- W3154648093 type Work @default.
- W3154648093 sameAs 3154648093 @default.
- W3154648093 citedByCount "103" @default.
- W3154648093 countsByYear W31546480932021 @default.
- W3154648093 countsByYear W31546480932022 @default.
- W3154648093 countsByYear W31546480932023 @default.
- W3154648093 crossrefType "journal-article" @default.
- W3154648093 hasAuthorship W3154648093A5000036560 @default.
- W3154648093 hasAuthorship W3154648093A5002455597 @default.
- W3154648093 hasAuthorship W3154648093A5003993218 @default.
- W3154648093 hasAuthorship W3154648093A5006067953 @default.
- W3154648093 hasAuthorship W3154648093A5012258151 @default.
- W3154648093 hasAuthorship W3154648093A5020987329 @default.
- W3154648093 hasAuthorship W3154648093A5026189241 @default.
- W3154648093 hasAuthorship W3154648093A5028130589 @default.
- W3154648093 hasAuthorship W3154648093A5028939852 @default.
- W3154648093 hasAuthorship W3154648093A5029140232 @default.
- W3154648093 hasAuthorship W3154648093A5031804038 @default.
- W3154648093 hasAuthorship W3154648093A5043379267 @default.
- W3154648093 hasAuthorship W3154648093A5048201566 @default.
- W3154648093 hasAuthorship W3154648093A5049507373 @default.
- W3154648093 hasAuthorship W3154648093A5060962650 @default.
- W3154648093 hasAuthorship W3154648093A5073018144 @default.
- W3154648093 hasAuthorship W3154648093A5075617216 @default.
- W3154648093 hasAuthorship W3154648093A5077529566 @default.
- W3154648093 hasAuthorship W3154648093A5077645027 @default.
- W3154648093 hasAuthorship W3154648093A5081596967 @default.
- W3154648093 hasAuthorship W3154648093A5085720070 @default.
- W3154648093 hasAuthorship W3154648093A5090047708 @default.
- W3154648093 hasBestOaLocation W31546480931 @default.
- W3154648093 hasConcept C126322002 @default.
- W3154648093 hasConcept C142724271 @default.
- W3154648093 hasConcept C159047783 @default.
- W3154648093 hasConcept C159654299 @default.
- W3154648093 hasConcept C168563851 @default.
- W3154648093 hasConcept C197934379 @default.
- W3154648093 hasConcept C203014093 @default.
- W3154648093 hasConcept C204787440 @default.
- W3154648093 hasConcept C22070199 @default.
- W3154648093 hasConcept C27081682 @default.
- W3154648093 hasConcept C2778375690 @default.
- W3154648093 hasConcept C2780868878 @default.
- W3154648093 hasConcept C2908647359 @default.
- W3154648093 hasConcept C71924100 @default.
- W3154648093 hasConcept C99454951 @default.
- W3154648093 hasConceptScore W3154648093C126322002 @default.